Stock Comparison

ABBV vs JNJ

AbbVie Inc vs Johnson & Johnson

The Verdict

JNJ takes this one.

ABBV

AbbVie Inc

0.1

out of 10

Distressed

Winner

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$381.1B

Market Cap

$557.1B

104.8

P/E Ratio

26.5

5.8%

Profit Margin

21.8%

95.6%

Return on Equity

26.3%

20.2

Debt-to-Equity

0.6

Moderate

Overall Risk

Conservative

0.1

DVR Score

1.0

The Deep Dive

ABBV0.1/10

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Full ABBV Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.